Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Moosa, Khalil"'
Autor:
Markus Eszlinger, Alexandra Stephenson, Shideh Mirhadi, Konrad Patyra, Michael F Moran, Moosa Khalil, Jukka Kero, Ralf Paschke
Publikováno v:
European Thyroid Journal, Vol 12, Iss 6, Pp 1-13 (2023)
Objective: Nonautoimmune hyperthyroidism (NAH) is rare and occurs due to a constitutively activating thyroid stimulating hormone receptor (TSHR) mutation. In contrast to other thyroid nodules, no further evaluation for malignancy is recommended for h
Externí odkaz:
https://doaj.org/article/ec09ffec7d2645cb934c4d925b01088d
Autor:
Markus Eszlinger, Paul Stewardson, John B McIntyre, Adrian Box, Moosa Khalil, Martin Hyrcza, Konstantin Koro, Dean Ruether, Jiahui Wu, Ralf Paschke
Publikováno v:
European Thyroid Journal, Vol 11, Iss 1, Pp 1-10 (2023)
Objective: The aim of the study was to identify patients with NTRK fusion-positive or RET fusion/mutation-positive thyroid cancers, who could benefit from neurotrophic tyrosine kinase receptor (NTRK) or receptor tyrosine kinase (RET) inhibitors. Meth
Externí odkaz:
https://doaj.org/article/b63abb63328d41eb93bcfefe209f6b41
Autor:
Steven Craig, Cynthia Stretch, Farshad Farshidfar, Dropen Sheka, Nikolay Alabi, Ashar Siddiqui, Karen Kopciuk, Young Joo Park, Moosa Khalil, Faisal Khan, Adrian Harvey, Oliver F. Bathe
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
Clinical management of papillary thyroid cancer depends on estimations of prognosis. Standard care, which relies on prognostication based on clinicopathologic features, is inaccurate. We applied a machine learning algorithm (HighLifeR) to 502 cases a
Externí odkaz:
https://doaj.org/article/8e7460e596574c6d98e9212285200400
Autor:
Jiahui Wu, Xun Yang Hu, Sana Ghaznavi, Susan Kinnear, Christopher John Symonds, Peter Grundy, Vicky M. Parkins, Priyanka Sharma, Debbie Lamb, Moosa Khalil, Martin Hyrcza, Shamir P. Chandarana, Janice L. Pasieka, Adrian Harvey, Joseph Warshawski, Robert Hart, Michael Deutschman, Derrick R. Randall, Ralf Paschke
Publikováno v:
Thyroid. 32:1509-1518
Publikováno v:
Diagnostic Cytopathology. 51
Autor:
Sana A. Ghaznavi, Hailey Clayton, Markus Eszlinger, Moosa Khalil, Christopher J. Symonds, Ralf Paschke
Publikováno v:
Acta Cytologica. 66:171-178
Introduction: The reported ROM within TBSRTC categories varies widely and depends on several factors in the clinical care pathway for thyroid nodules, including sonographic risk stratification, cytology expertise, selection criteria for surgical rese
Autor:
Steven Craig, Cynthia Stretch, Farshad Farshidfar, Dropen Sheka, Nikolay Alabi, Ashar Siddiqui, Karen Kopciuk, Young Joo Park, Moosa Khalil, Faisal Khan, Adrian Harvey, Oliver F. Bathe
SUMMARYClinical management of papillary thyroid cancer depends on estimations of prognosis. Standard care, which relies on prognostication based on clinicopathologic features, is inaccurate. We applied a machine learning algorithm (HighLifeR) to 502
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f87e8ca65cca35086697ca4d1cbd4e0
https://doi.org/10.1101/2022.12.27.522039
https://doi.org/10.1101/2022.12.27.522039
Autor:
Jiahui Wu, Hu Xun Yang, Sana Ghaznavi, Susan Kinnear, Christopher Symonds, Peter Grundy, Vicky Parkins, Priyanka Sharma, Debbie Lamb, Moosa Khalil, Martin Hyrcza, Shamir Chandarana, Janice Pasieka, Adrian Harvey, Joseph Warshawski, Robert Hart, Michael Deutschman, Derrick Randall, Ralf Paschke
Publikováno v:
Endocrine Abstracts.
Autor:
Ralf Paschke, Aaron Gillmor, Sorana Morrissy, Paul Stewardson, Helen Huang, John B. McIntyre, Moosa Khalil, Markus Eszlinger
Publikováno v:
Genes, Chromosomes and Cancer. 60:531-545
Advanced cancers frequently show histologic and molecular intratumoral heterogeneity. Therefore, we comprehensively characterized advanced, metastatic, radioiodine-resistant (RAIR) thyroid carcinomas at the molecular level in the context of histologi
Autor:
Markus Eszlinger, Paul Stewardson, John B McIntyre, Adrian Box, Moosa Khalil, Martin Hyrcza, Konstantin Koro, Dean Ruether, Jiahui Wu, Ralf Paschke
Publikováno v:
European Thyroid Journal. 11
Objective The aim of the study was to identify patients with NTRK fusion-positive or RET fusion/mutation-positive thyroid cancers, who could benefit from neurotrophic tyrosine kinase receptor (NTRK) or receptor tyrosine kinase (RET) inhibitors. Metho